Runtogen
Menu
Runtogen integrates cutting-edge technologies and scientific expertise to deliver end-to-end antibody discovery solutions. From antigen design to lead identification, we accelerate your therapeutic and research programs with precision and reliability.
With state-of-the-art facilities and a team of experienced scientists, we offer a seamless pathway from target antigen identification to lead antibody candidates. Our proprietary technologies ensure precision and efficiency in delivering innovative antibody solutions through advanced antibody discovery platforms.
Tailored solutions for monoclonal, bispecific, and recombinant antibodies. Our Common Light Chain Platform minimizes mispairing for bispecifics, and our Nanobody Platform enables single-domain antibodies with superior tissue penetration.
Rapid identification of therapeutic candidates using advanced automation and functional assays, ensuring faster timelines for your programs.
Fully integrated services from antigen design and immunization to antibody engineering and validation—all under one roof.
Stringent QC processes at every step ensure reproducible, high-quality results you can trust for research or clinical development.
High-precision antigen design using peptide-based and protein-based strategies to maximize success for even the most challenging targets.
We employ multiple advanced methods:
Automated, analytics-driven screening identifies top-performing candidates rapidly. Functional screening ensures optimal selection for therapeutic applications.
Enhance performance with affinity maturation, humanization, Fc optimization, and AI-based engineering to predict and refine antibody characteristics.
Rigorous testing for specificity, sensitivity, and functionality using ELISA, flow cytometry, Western blot, and off-target screening to ensure target specificity, especially for membrane proteins.
Supporting development of antibody therapeutics for oncology, infectious diseases, autoimmune disorders, and more.
High-affinity antibodies for diagnostic assays, including ELISA, rapid tests, and imaging reagents.
Essential tools for exploring molecular mechanisms, cell signaling, and target validation.
Engineered to bind two distinct targets simultaneously, expanding therapeutic strategies and specificity for next-generation biologics.
Specialized MPS AB5000 platform ensures high-specificity binding for challenging membrane targets, crucial for CAR-T and biologics success.
Leverage neural networks to model antibody-antigen interactions and virtually generate innovative antibody candidates with optimized characteristics.
Partner with Runtogen for faster timelines, expert support, and cutting-edge platforms. Let’s discuss your project today.
Contact our team →